Relative frequency of clinically significant predictive, prognostic, and diagnostic markers and their combination in the profiled solid tumors. All 14 analyzed cancer types (n = 88 569) include non-small cell lung cancer (n = 22 152), colorectal cancer (n = 13 193), breast cancer (n = 11 016), ovarian cancer (n = 6999), prostate cancer (n = 6513), pancreatic adenocarcinoma (n = 6168), gastroesophageal adenocarcinoma (n = 4762), unknown primary carcinoma (n = 4607), urothelial carcinoma (n = 3236), cholangiocarcinoma (n = 2901), melanoma (n = 2743), glioma (n = 2350), head and neck squamous cell carcinoma (n = 1787), and uveal melanoma (n = 142). Note that the markers in unknown primary carcinoma are predictive pan-cancer markers (TMB ≥ 10 mut/Mb, MSI-high, and NTRK1/2/3 fusion) as well as investigational targets that are associated with therapy approvals in other tumor types.